Multiple scheduled U.S. IPOs on Nasdaq and NYSE, including Lycia Therapeutics targeting a $250 million raise with expected trading October 23 and several smaller deals priced for late October through mid-November, form the core driver of current sentiment. Year-to-date, 259 IPOs have priced on U.S. exchanges as of October 22, though activity has moderated from prior-year levels amid elevated Treasury yields, selective investor demand, and volatility in sectors like data centers. Recent listings such as City Therapeutics and Amaero demonstrate continued execution, while delays by larger candidates like OpenAI underscore caution. With the resolution window closing in roughly ten weeks, these near-term filings and pricing calendars anchor trader expectations for at least one additional listing before year-end.